PolyPid (NASDAQ:PYPD) Earns "Buy" Rating from HC Wainwright

Key Points

• PolyPid's stock has been given a "Buy" rating by HC Wainwright, with a target price of $13.00, suggesting a potential upside of 268.79% from its previous close.
• Despite the positive outlook, the company reported an earnings miss with an EPS of ($0.78), falling short of analysts' expectations of ($0.53).
• AIGH Capital Management recently increased its holdings in PolyPid by 27%, indicating growing institutional interest in the company.

PolyPid (NASDAQ:PYPD - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $13.00 price objective on the stock. HC Wainwright's price objective would indicate a potential upside of 276.81% from the company's previous close. HC Wainwright also issued estimates for PolyPid's Q3 2025 earnings at ($0.39) EPS, FY2025 earnings at ($2.02) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($0.20) EPS and FY2029 earnings at $1.46 EPS.

Several other brokerages have also commented on PYPD. Wall Street Zen upgraded shares of PolyPid to a "hold" rating in a research note on Saturday, July 12th. Roth Capital set a $9.00 target price on shares of PolyPid and gave the company a "buy" rating in a research note on Wednesday, June 18th. Finally, JMP Securities lowered their target price on shares of PolyPid from $16.00 to $14.00 and set a "market outperform" rating on the stock in a research note on Tuesday, June 17th. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $12.40.

PolyPid Stock Up 0.6%

Shares of PYPD traded up $0.02 during mid-day trading on Wednesday, hitting $3.45. 62,483 shares of the company's stock were exchanged, compared to its average volume of 79,908. The firm has a fifty day moving average of $3.50 and a two-hundred day moving average of $3.06. PolyPid has a twelve month low of $2.30 and a twelve month high of $3.93. The stock has a market cap of $54.86 million, a price-to-earnings ratio of -0.90 and a beta of 1.40.

PolyPid (NASDAQ:PYPD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.25). On average, equities analysts predict that PolyPid will post -1.79 earnings per share for the current year.

Institutional Trading of PolyPid

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Lumbard & Kellner LLC acquired a new stake in PolyPid in the 2nd quarter worth $135,000. J. Goldman & Co LP acquired a new stake in PolyPid in the 4th quarter worth $391,000. Finally, AIGH Capital Management LLC grew its position in PolyPid by 13.6% in the 1st quarter. AIGH Capital Management LLC now owns 940,381 shares of the company's stock worth $2,548,000 after purchasing an additional 112,514 shares during the last quarter. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.